Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 20, 2022 08:00 ET | Source: Chimerix, Inc.

Chimerix to Present at B. Riley Virtual Oncology Conference

DURHAM, N.C., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
January 18, 2022 16:01 ET | Source: Chimerix, Inc.

Chimerix Announces Publication of Positive ONC201 Data from Phase 2 Study in Neuroendocrine Tumors in Clinical Cancer Research

DURHAM, N.C., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
January 03, 2022 16:45 ET | Source: Chimerix, Inc.

Chimerix to Present at Virtual H.C. Wainwright BioConnect 2022 Conference

DURHAM, N.C., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
November 19, 2021 07:00 ET | Source: Chimerix, Inc.

Chimerix Announces Positive ONC201 Data in Recurrent H3 K27M-mutant Diffuse Midline Glioma to Be Presented at the Society for Neuro-Oncology Annual Meeting

– Plenary Session Presentation on Saturday, November 20 – – Company to Host Conference Call at 8:30 a.m. ET on Monday, November 22 – DURHAM, N.C., Nov. 19, 2021 (GLOBE NEWSWIRE) --...
November 12, 2021 08:00 ET | Source: Chimerix, Inc.

Chimerix to Present at Jefferies London Healthcare Conference

DURHAM, N.C., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX),a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients...
November 11, 2021 07:00 ET | Source: Chimerix, Inc.

Chimerix Announces Upcoming Presentations at the Society for Neuro-Oncology Annual Meeting 2021

DURHAM, N.C., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
November 04, 2021 07:05 ET | Source: Chimerix, Inc.

Chimerix Reports Third Quarter 2021 Financial Results and Provides Operational Update

– Announced Positive Topline Results from ONC201 in Recurrent H3 K27M-mutant Glioma – –U.S. Food and Drug Administration (FDA) Published Article Summarizing Benefit-Risk Assessment of TEMBEXA for...
November 04, 2021 07:00 ET | Source: Chimerix, Inc.

Chimerix Announces Positive Topline Results for ONC201 in Recurrent H3 K27M-mutant Glioma

– Blinded Independent Central Review (BICR) of ONC201 Cohort Reported 20.0% Objective Response Rate (ORR) by RANO-HGG Criteria – – Compelling Durability of Responses with 11.2 Month Median Duration...
November 01, 2021 08:00 ET | Source: Chimerix, Inc.

Chimerix to Present at Credit Suisse 30th Annual Healthcare Conference

DURHAM, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
October 28, 2021 07:00 ET | Source: Chimerix, Inc.

Chimerix to Report Third Quarter 2021 Financial Results and Provide an Operational Update on November 4, 2021

DURHAM, N.C., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing medicines for patients facing deadly diseases that meaningfully improves and extends...